Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

A phenotype-based profiling test can help predict whether a patient might respond better to one antiobesity medicine or ...

New data and analyses presented at the American Diabetes Association’s annual meeting highlight the priorities for the next ...

The partnership between the Danish pharmaceutical giant and the splashy telehealth firm Hims & Hers was strained from the start.

SINGAPORE - Media OutReach Newswire - 12 July 2025 - A significant advancement in weight management has arrived for Singaporeans. Novo Nordisk, a global healthcare company focused on defeating serious ...

Imugene (ASX:IMU) will forge ahead with a planned pivotal US trial for its blood cancer therapy Azer-cel, having recorded ...

A psychologist has revealed what effect Ozempic can have on a person's sex drive and how that ties into the 'reward system'. Now, people are using Ozempic to manage their weight, but its manufacturer ...

The ASX opened 0.15% down but by lunch time in the east, the local bourse had pulled off a quiet comeback, inching up toward ...

A new fight is brewing over the Medicare drug price negotiation program after the Trump administration proposed to consider ...

In 2022, over 1 billion people were affected by obesity, driving innovation in therapeutic advancements. Emerging treatments focus on appetite contro ...

An article by Thai business platform ลงทุนแมน, recently shared by the Thai-Swedish Chamber of Commerce, sheds light on what ...

Danish pharmaceutical company Novo Nordisk has officially launched its once-weekly injectable weight management drug, Wegovy® (semaglutide 2.4mg), in Singapore. The treatment received regulatory ...